HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yu-Ling Tsai Selected Research

fatty acid-binding protein 6

2/2022Fatty Acid Binding Protein 6 Inhibition Decreases Cell Cycle Progression, Migration and Autophagy in Bladder Cancers.
10/2021Inhibition of FABP6 Reduces Tumor Cell Invasion and Angiogenesis through the Decrease in MMP-2 and VEGF in Human Glioblastoma Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yu-Ling Tsai Research Topics

Disease

7Neoplasms (Cancer)
06/2022 - 06/2010
3Inflammation (Inflammations)
01/2019 - 10/2016
2Urinary Bladder Neoplasms (Bladder Cancer)
05/2022 - 02/2022
2Glioblastoma (Glioblastoma Multiforme)
10/2021 - 09/2020
2Fibrosis (Cirrhosis)
01/2020 - 07/2017
2Colonic Neoplasms (Colon Cancer)
10/2012 - 06/2010
1Adenocarcinoma of Lung
06/2022
1Gastrointestinal Neoplasms (Gastrointestinal Cancer)
06/2022
1Lung Neoplasms (Lung Cancer)
06/2022
1Wounds and Injuries (Trauma)
01/2022
1Colorectal Neoplasms (Colorectal Cancer)
10/2021
1Chronic Renal Insufficiency
01/2021
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2021
1Lupus Nephritis
01/2021
1Carcinogenesis
09/2020
1Glioma (Gliomas)
09/2020
1Ureteral Obstruction
01/2020
1IGA Glomerulonephritis (IGA Nephropathy)
01/2017
1Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal)
08/2014
1Proteinuria
08/2014
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
05/2009
1Tic Disorders (Tic Disorder)
05/2009
1Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
05/2009
1Infections
05/2009
1Myocarditis (Carditis)
05/2009

Drug/Important Bio-Agent (IBA)

3Bile Acids and Salts (Bile Acids)IBA
06/2022 - 10/2021
3InflammasomesIBA
01/2021 - 01/2017
3CytokinesIBA
01/2020 - 10/2016
2Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
06/2022 - 05/2022
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2022 - 10/2021
2Messenger RNA (mRNA)IBA
05/2022 - 09/2020
2fatty acid-binding protein 6IBA
02/2022 - 10/2021
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
10/2021 - 06/2010
2Temozolomide (Temodar)FDA LinkGeneric
10/2021 - 09/2020
1LipidsIBA
06/2022
1CarcinogensIBA
06/2022
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
06/2022
1Proteins (Proteins, Gene)FDA Link
05/2022
1Proteasome Endopeptidase Complex (Proteasome)IBA
05/2022
1benzyloxycarbonylleucyl-leucyl-leucine aldehydeIBA
05/2022
1Cisplatin (Platino)FDA LinkGeneric
02/2022
1Saline SolutionIBA
01/2022
1Carrier Proteins (Binding Protein)IBA
10/2021
1benzamideIBA
01/2021
1Pharmaceutical PreparationsIBA
01/2021
1NF-kappa B (NF-kB)IBA
09/2020
1Therapeutic UsesIBA
01/2020
1ginsenoside M1IBA
01/2020
1Proline (L-Proline)FDA Link
10/2016
1Alanine (L-Alanine)FDA Link
10/2016
1Phosphotransferases (Kinase)IBA
10/2016
1AntioxidantsIBA
08/2014
1Dinoprostone (PGE2)FDA Link
08/2014
1osthol (osthole)IBA
08/2014
1Ethanol (Ethyl Alcohol)IBA
10/2012
1Caspase 9IBA
10/2012
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
10/2012
1chicoric acidIBA
10/2012
1Telomerase (Telomerase Reverse Transcriptase)IBA
10/2012
1CateninsIBA
10/2012
1Arginine (L-Arginine)FDA Link
06/2010
1Angiogenic ProteinsIBA
06/2010
1tyramine-deoxysorbitolIBA
05/2009

Therapy/Procedure

1Aftercare (After-Treatment)
05/2022
1Drug Therapy (Chemotherapy)
01/2022
1Radiotherapy
01/2022
1Therapeutics
01/2019